Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2013-12-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
关于出售可供出售金融资产的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of selling available-for-sale financial assets by the company 嘉事堂药业股份有限公司. It details the authorization by the shareholders, the transaction specifics including shares sold, prices, and the impact on net profit. The document is short (930 characters) and focuses on a specific capital transaction rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed analysis but rather an update on a financing-related activity. Therefore, it fits best under Capital/Financing Update (CAP).
2013-12-18 Chinese
关于出资设立安徽嘉事谊诚医疗器械有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 嘉事堂药业股份有限公司 regarding its investment to establish a new company 安徽嘉事谊诚医疗器械有限公司. It details the investment amounts, shareholders, board structure, and other contractual terms. The document is a formal public announcement of a capital investment and company formation, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is 2663 characters, which is relatively short and consistent with an announcement. The content fits best with a Capital/Financing Update (CAP) as it relates to the company's financing activity and capital investment in a new subsidiary. Therefore, the correct classification is CAP with high confidence.
2013-12-02 Chinese
2013年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and proceedings of the 2013 second extraordinary shareholders' meeting of a company. It details the legal compliance of the meeting's convening, attendance, voting procedures, and results. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a specific shareholders' meeting. It is not an announcement of voting results per se, but a legal opinion on the meeting's legality and procedures. Therefore, it fits best under Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and shareholder meetings, but not a direct governance report or voting result declaration.
2013-12-02 Chinese
拟收购江苏益科达医疗科技有限公司等两家公司项目资产评估报告
M&A Activity Classification · 95% confidence The document is titled as an "资产评估报告" which translates to "Asset Valuation Report" or "Asset Appraisal Report." It is prepared by an asset appraisal company for 嘉事堂药业股份有限公司 regarding its planned acquisition of 江苏益科达医疗科技有限公司 and another company. The report includes detailed valuation methods, asset and liability assessments, financial data, and legal and regulatory references related to asset valuation and acquisition. It is a comprehensive standalone asset evaluation report used to support a merger or acquisition transaction. This type of document is not a general annual report, earnings release, or management discussion, but a specialized valuation report related to M&A activity. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category "M&A Activity" (Code: TAR). Since this is an asset valuation report prepared for an acquisition project, it fits best under the "M&A Activity" category rather than a general audit report or regulatory filing. The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is TAR with high confidence.
2013-12-02 Chinese
拟收购江苏益科达医疗科技有限公司等两家单位的审计报告（2013年1月1日至2013年09月30日止）
Audit Report / Information Classification · 95% confidence The document is titled as an audit report for the acquisition of two companies by 嘉事堂药业股份有限公司, covering the period from January 1, 2013 to September 30, 2013. It contains detailed financial statements including balance sheets, profit and loss statements, and extensive notes on accounting policies and estimates. The presence of an auditor's opinion, detailed financial data, and accounting notes indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Audit Report / Information (AR). 9M 2013
2013-12-02 Chinese
拟收购广州吉健商贸有限公司等五家公司项目资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" which translates to "Asset Evaluation Report" or "Asset Appraisal Report". It is prepared by an asset evaluation company for 嘉事堂药业股份有限公司 regarding its planned acquisition of five companies including 广州吉健商贸有限公司. The report includes detailed asset valuation methods, asset and liability values, and financial data as of a specific valuation date (2013-09-30). It is a comprehensive standalone asset appraisal report used to support the acquisition decision. This type of document is not a full annual or interim financial report, nor is it an earnings release or management discussion. It is also not a regulatory announcement or a proxy statement. It fits best under the category of Audit Report / Information (AR) because it is a standalone professional valuation report related to a transaction, providing applied valuation principles and results, but not a full annual report or interim financial report. The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. 9M 2013
2013-12-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.